Rheogene

Norristown, United States Founded: 2003 • Age: 23 yrs Acquired By UPMC
Gene-based therapeutic products are developed using modulation platforms.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Rheogene

Rheogene is a company based in Norristown (United States) founded in 2003 was acquired by UPMC in February 2004. Rheogene operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

  • Headquarter Norristown, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    UPMC

    (Feb 17, 2004)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Rheogene

Premium access

Detailed funding history for Rheogene

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Rheogene

Rheogene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include UPMC.

All
Institutional
Investor Description Founded Year Domain Location
Multispecialty hospitals are operated as a nationwide chain.
Locked Locked Locked
Premium access

Investor details for Rheogene

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Rheogene

Investments
Premium access

Investment portfolio details for Rheogene

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Rheogene

Premium access

Detailed financials for Rheogene

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Rheogene Comparisons

Rheogene Primary company
Description
Gene-based therapeutic products are developed using modulati...
Location
Norristown, United States
Founded Year
2003
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Rheogene

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Rheogene

Rheogene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Locked Locked Locked
Gene therapies for rare diseases are developed to treat patients.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
Provider of cell therapies to treat cancer and hematologic conditions
Premium access

Detailed competitors of Rheogene

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Rheogene

Premium access

Complete news archive for Rheogene

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rheogene

Rheogene was founded in 2003.

Rheogene is headquartered in Norristown, United States. It is registered at Norristown, Pennsylvania, United States.

Rheogene was founded in 2003 and is headquartered in Norristown, United States. Operations focus on biotechnology, specifically the development of gene-based therapeutic products. The RheoSwitch therapeutic system and direct recombinase platform are utilized to modulate gene expression, supported by the Ultravector system. Applications include cellular and gene therapies, enhanced protein expression, and genomics research. Services are provided through these proprietary technologies.

Rheogene's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Rheogene has 1 investor. Key investors include UPMC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available